/Companies

Rejuvenation Technologies Inc.

YC S18

San Francisco, US · Founded 2016 · 2 employees · 14 known investors

Find your way into Rejuvenation Technologies Inc.

Sign up to see every warm intro you have to Rejuvenation Technologies Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Rejuvenation Technologies Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.

Also known as Rejuvenation Technologies · Rejuvenation Technologies Inc., Rejuvenation Technologies

BiotechDeep TechHealthtechLongevityAnti-AgingGene TherapyNanomedicineUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S18)

Rejuvenation Technologies Inc. was founded in 2016 by Glenn Markov and John Ramunas.

GMGlenn Markov
Glenn MarkovCo-founder · Chief Operating OfficerGlenn Markov holds a PhD in Genetics from Stanford, which he completed in 2018.
JRJohn Ramunas
John RamunasCo-Founder, CEOJohn Ramunas holds a PhD and conducted telomere research at Stanford in Helen Blau's lab; he is founder of Rejuvenation Technologies, which is developing mRNA-based telomere extension and has received FDA INTERACT clearance, Khosla Ventures seed funding, and admission to Y Combinator.
WOWill Olsen
Will OlsenVice President Of Development2019–2021Founder at Engage Bio

Investors · 14

Agrolimen Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

DevXreportedAhmedabad

How we know: Y Combinator's founder network · Not right? Tell us

Reinforced VenturesreportedPittsburgh

How we know: Y Combinator's founder network · Not right? Tell us

Saga VenturesreportedAustin

How we know: Y Combinator's founder network · Not right? Tell us

Shanda GroupreportedRedwood City

How we know: Y Combinator's founder network · Not right? Tell us

SP Investment Fundreported

How we know: Y Combinator's founder network · Not right? Tell us

The Capital PartnershipreportedLondon

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 7

Nuntius TherapeuticsNuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.
Rejuvenate BioRejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
Sixfold BioscienceSixfold develops RNA delivery technology for the biotech industry. The company was founded by an oncologist and plant scientist and focuses on advancing RNA-based therapeutic approaches through proprietary delivery methods.
NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
LifespanLifespan Research Institute invests in biotechnology startups developing regenerative medicine and longevity therapies. The institute funds companies working on age-related disease treatment, including cellular senescence, tissue damage repair, and cancer therapeutics.
Read on Scientific AmericanScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.

Companies working in the same space as Rejuvenation Technologies Inc..

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$626.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$300K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2020$272.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Rejuvenation Technologies, Inc.

Frequently asked questions

What does Rejuvenation Technologies Inc. do?
Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Who founded Rejuvenation Technologies Inc.?
Rejuvenation Technologies Inc. was founded by Glenn Markov, John Ramunas in 2016.
Who are Rejuvenation Technologies Inc.'s investors?
Rejuvenation Technologies Inc.'s investors include Asymmetry Ventures, Gold Dragon Ventures, Lifespan Vision Ventures, Startups, StartX, Y Combinator, Agrolimen Ventures, DevX and 6 more.
Where is Rejuvenation Technologies Inc. headquartered?
Rejuvenation Technologies Inc. is headquartered in San Francisco, US.